Cargando…
Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report
Posterior reversible encephalopathy syndrome (PRES) is an uncommon transient neuroradiological phenomenon that develops vasogenic cerebral edema and could be caused by some pharmacological agents, such as molecular-specific target agents. Lenvatinib belongs to the tyrosine kinase inhibitors and was...
Autores principales: | Buenaventura, Daisy Carolina, Vargas-Sierra, Hernando, Aristizabal-Henao, Natalia, Torres-Grajales, Jose Luis, Aguilar-Londono, Carolina, Gutierrez-Restrepo, Johnayro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Brieflands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676670/ https://www.ncbi.nlm.nih.gov/pubmed/38028246 http://dx.doi.org/10.5812/ijem-136900 |
Ejemplares similares
-
Ectopic Cushing syndrome in Colombia
por: Lopez-Montoya, Vanessa, et al.
Publicado: (2020) -
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma
por: Tseng, Yu-Ju, et al.
Publicado: (2022) -
Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer
por: Matsuura, Yuki, et al.
Publicado: (2023) -
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma
por: Osawa, Yoko, et al.
Publicado: (2017) -
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
por: Chae, Young Kwang, et al.
Publicado: (2018)